Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bull 2X Shares

27.81
-1.1280-3.90%
Pre-market: 27.79-0.0226-0.08%08:11 EDT
Volume:82.12K
Turnover:2.37M
Market Cap:17.38M
PE:- -
High:30.31
Open:29.02
Low:27.69
Close:28.94
52wk High:35.13
52wk Low:16.34
Shares:625.00K
Float Shares:625.00K
Volume Ratio:1.85
T/O Rate:13.14%
Dividend:3.16
Dividend Rate:11.36%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly Price Target Maintained with a $1250.00/Share by TD Cowen

Dow Jones
·
Sep 22

Viking Therapeutics Stock Surges 35%. It Could Challenge Lilly and Novo's Obesity Empire

Dow Jones
·
Sep 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 22

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 22

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Dow Jones
·
Sep 22

Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site

MT Newswires Live
·
Sep 22

Eli Lilly: Breaks Ground on Fifth U.S. API Manufacturing Site in Houston

THOMSON REUTERS
·
Sep 22

Eli Lilly: Houston Facility to Manufacture Active Pharmaceutical Ingredients for Medicines Like Foundayo

THOMSON REUTERS
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21